Neuroendocrine Tumors

Latest News

Data from the phase 3 CABINET study support the approval of cabozantinib in patients with pancreatic neuroendocrine tumors.
FDA Approves Cabozantinib in Pancreatic/Extra-Pancreatic Neuroendocrine Tumors

March 26th 2025

Data from the phase 3 CABINET study support the approval of cabozantinib in patients with pancreatic and extra-pancreatic neuroendocrine tumors.

Phase 3 data show that ITM-11 produced favorable safety results among patients with gastroenteropancreatic neuroendocrine tumors.
Investigational Agent Improves PFS Vs Everolimus in Grade 1/2 GI NETs

January 29th 2025

A phase 2 trial revealed survival with ramucirumab plus somatostatin was consistent with other VEGF pathways in treating advanced neuroendocrine tumors.
Ramucirumab/Somatostatin Displays Prolonged Survival in Advanced NET

January 27th 2025

Investigators are assessing treatment with ELC-100 among patients with pancreatic neuroendocrine tumors as part of a phase 1/2 trial.
FDA Grants Orphan Drug Designation to ELC-100 in Pancreatic NETs

January 13th 2025

FDA acceptance is based on phase 3 CABINET trial results, with cabozantinib showing a PFS improvement in patients with pancreatic neuroendocrine tumors.
FDA Accepts sNDA for Cabozantinib in Pancreatic Neuroendocrine Tumors

August 8th 2024

Video Interviews
Podcasts
Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

More News